Skip to content

Study · Observational study · n = 58 · 2026

3 results

Short-term effect of tirzepatide on serum calcitonin in adults with obesity.

Angelopoulos N, Simeakis G, Androulakis I, Rizoulis A, Boniakos A, Mentzelopoulou P, Korakovouni A, Zianni D, Petkova V, Livadas S, Paparodis R

Endocrine4 May 2026

PMID42081121 (opens in a new tab)DOI10.1007/s12020-026-04655-y (opens in a new tab)PepBankPUB-42081121
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In adults with obesity, serum calcitonin rose from 2.7 to 3.2 pg/mL after 12 weeks of tirzepatide, a small but statistically significant increase.

    In plain wordsIn adults with obesity, calcitonin rose slightly, from 2.7 to 3.2 pg/mL, after 12 weeks of tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSerum calcitonin change
    Study

    n = 58

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    serum calcitonin
    2.7 pg/mL
    baseline
    serum calcitonin
    3.2 pg/mL
    12 weeks

    Source sentences

    Summary
    Mean baseline calcitonin was 2.7 ± 3.0 pg/mL, increasing to 3.2 ± 3.7 pg/mL post-treatment.
    3 context sentences
    Summary · context
    This change was statistically significant (Wilcoxon Z = − 3.0, p = 0.003) with a moderate effect size (r = 0.4), despite a small absolute increase.
    Summary · context
    In this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss.
    Summary · context
    Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment.
  2. 02HumanObservational studySafety outcome

    In adults with obesity, no participant exceeded the calcitonin threshold of 20 pg/mL after 12 weeks of tirzepatide.

    In plain wordsIn adults with obesity, no one went above the calcitonin safety threshold of 20 pg/mL after 12 weeks of tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeCalcitonin above 20 pg/mL
    Study

    n = 58

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    calcitonin threshold
    20 pg/mL
    clinical threshold

    Source sentences

    Summary
    No participant exceeded the clinical calcitonin threshold of 20 pg/mL.
    2 context sentences
    Summary · context
    In this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss.
    Summary · context
    Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment.
  3. 03HumanObservational studySafety outcome

    In adults with obesity, no thyroid nodules were detected on ultrasound after 12 weeks of tirzepatide.

    In plain wordsIn adults with obesity, ultrasound found no thyroid nodules after 12 weeks of tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeThyroid nodules on ultrasound
    Study

    n = 58

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No thyroid nodules were detected on ultrasound.
    2 context sentences
    Summary · context
    In this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss.
    Summary · context
    Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.